Bausch Health Co. Inc. (BHC) Reports In-Line Q2 Revenue, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Bausch Health (BHC) Results 'Good', Solta Could Be Valued at $2.5B+ - Cowen
August 3, 2021 10:54 AM EDTCowen analyst Ken Cacciatore reiterated an Outperform rating and $40.00 price target on Bausch Health Companies (NYSE: BHC) following results and news it plans to IPO the aesthetics Solta division.
The analyst commented, "BHC reported a good Q2 with revs and earnings essentially in-line; the... More
